Kevin Koch, President, CSO at Array Biopharma, holds 927.16K shares in Array Biopharma (Ticker: ~ARRY), holds ― shares in Viridian Therapeutics (Ticker: VRDN), holds 353.26K shares in Edgewise Therapeutics (Ticker: EWTX).

See the Hottest Stocks Based on Insider Trading >

Kevin Koch
Array Biopharma (~ARRY)
President, CSO

Not Ranked

Kevin Koch has not reported sufficient informative transactions and therefore cannot be ranked.

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

100.00%

EWTX

0.00%

VRDN

A breakdown of Kevin Koch's holdings

See the Top Stocks by Insiders

Insider Roles

Edgewise Therapeutics
(EWTX)

President & CEO, Director

Viridian Therapeutics
(VRDN)

Director

Roles that Kevin Koch holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

Array Biopharma
(~ARRY)

Rating:Informative Buy

Date:Nov 13, 2009 - Nov 13, 2010

Return:+59.40%

The most profitable trade made by Kevin Koch

See the Latest Stocks Traded by Insiders

Kevin Koch's Trading History

~ARRY

Array Biopharma

Jul 25, 2013

―

Uninformative Sell

75.06K

$44.36M

VRDN

Viridian Therapeutics

―

Director

―

EWTX

Edgewise Therapeutics

Feb 07, 2025

President & CEO, Director

Uninformative Buy

13.35K

$9.56M

List of latest transactions for each holding click on a transaction to see Kevin Koch's performance on stock

See All Insider Trading from Today

Kevin Koch insider profile FAQ

What is the percentage of profitable transactions made by Kevin Koch?

The percentage of profitable transactions made by Kevin Koch is ―.

What is the average return per transaction made by Kevin Koch?

The average return per transaction made by Kevin Koch is ―.

What stocks does Kevin Koch hold?

Kevin Koch holds: ~ARRY, VRDN, EWTX stocks.

What was Kevin Koch’s latest transaction?

Kevin Koch latest transaction was an Uninformative Sell of $75.06K.

What was Kevin Koch's most profitable transaction?

Kevin Koch’s most profitable transaction was an Informative Buy of ~ARRY stock on November 13, 2009. The return on the trade was 59.40%.

What is Kevin Koch's role in Array Biopharma?

Kevin Koch's role in Array Biopharma is President, CSO.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Kevin Koch Insider Profile

Kevin Koch Array Biopharma (~ARRY)President, CSO